Latest Breaking News On - Garth virgin - Page 1 : comparemela.com

Back to the future
pharmatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmatimes.com Daily Mail and Mail on Sunday newspapers.

Daiichi sankyoDaiichi sankyo europeAffairs specialty medicine at daiichi sankyo europeEuropean society of cardiologyGarth virginEuropean societyExecutive directorMedical affairs specialty medicine

Daiichi Sankyo: European observational study SANTORINI shows LDL-C levels remain higher than recommended goals and combination therapies are under-utilised in patients at very high or high cardiovascular risk

Daiichi Sankyo: European observational study SANTORINI shows LDL-C levels remain higher than recommended goals and combination therapies are under-utilised in patients at very high or high cardiovascular risk
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

City ofUnited kingdomKausik rayWolfgang schiesslDaiichi sankyoGarth virginDaiichi sankyo europeDaiichi sankyo europe gmbProfessor of public healthAmerican college of cardiologyPortfolio communicationsSustainable development of societyEuropean society of cardiologyJournal of the american college cardiologyInnovative global healthcare companyEuropean medicines agency

Daiichi Sankyo Europe: New two-years follow-up data from ETNA-AF-Europe reaffirms benefit of LIXIANA (edoxaban) in people with atrial fibrillation

(0) Large routine clinical practice study, ETNA-AF-Europe, demonstrates continued benefits of edoxaban across age groups and supports treatment in elderly patient populations, in line with those observed in ETNA-AF after one year and in ENGAGE AF-TIMI 48 ETNA-AF-Europe is part of the global ETNA-AF programme, which is the largest prospective, non-interventional study investigating a single non-vitamin K antagonist oral anticoagulant (NOAC) to date Data presented at the annual scientific meeting of the European Heart Rhythm Association Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced the presentation of new routine clinical practice outcomes data confirming, in line with the randomised clinical trial data, the consistent effectiveness and safety profile of LIXIANA

Noord hollandThe netherlandsWolfgang schiesslDaiichi sankyoGarth virginDaiichi sankyo europeDaiichi sankyo europe gmbEuropean heart rhythm associationAtrial fibrillation at university of amsterdamAffairs specialty medicines at daiichi sankyo europeAmsterdam university medical centersDaiichi sankyo groupPortfolio communicationsEdoxaban clinical research programmeSankyo europeCardiac electrophysiology

New two-years follow-up data from ETNA-AF-Europe reaffirms benefit of LIXIANA® (edoxaban) in people with atrial fibrillation

New two-years follow-up data from ETNA-AF-Europe reaffirms benefit of LIXIANA® (edoxaban) in people with atrial fibrillation 04/26/2021 | 03:01am EDT Send by mail : Message : Required fields Large routine clinical practice study, ETNA-AF-Europe, demonstrates continued benefits of edoxaban across age groups and supports treatment in elderly patient populations, in line with those observed in ETNA-AF after one year and in ENGAGE AF-TIMI 48 ETNA-AF-Europe is part of the global ETNA-AF programme, which is the largest prospective, non-interventional study investigating a single non-vitamin K antagonist oral anticoagulant (NOAC) to date Data presented at the annual scientific meeting of the European Heart Rhythm Association Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) today announced the presentation of new routine clinical practice outcomes data confirming, in line with the randomised clinical trial data, the consistent effectiveness and safety profile of LIXIANA

Noord hollandThe netherlandsDaiichi sankyoGarth virginDaiichi sankyo europeEuropean heart rhythm associationAtrial fibrillation at university of amsterdamAffairs specialty medicines at daiichi sankyo europeAmsterdam university medical centersDaiichi sankyo groupEdoxaban clinical research programmeCardiac electrophysiologyAtrial fibrillationEdoxaban treatmentSankyo groupPharma innovator